There is a recognition that breast cancer is a collection of heterogeneous diseases divided into subtypes based on combined molecular features such as hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) status.
The current molecular classification divides breast cancer into five groups luminal A, luminal B, HER-2, basal and normal breast-like. Further grouping of these subgroups seems possible and necessary.